Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford, England) 2017; 56 (6): 865–868.
Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S-C et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2015; 74 (8): 1530–1536.
Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP . The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013; 72 (8): 1315–1320.
Johnson AE, Gordon C, Palmer RG, Bacon PA . The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38 (4): 551–558.
Content.digital.nhs.uk. (2017). Find data - NHS Digital. [online] Available at: http://content.digital.nhs.uk/searchcatalogue?productid=24706&q=+title%3a%22prescription+cost+analysis%22&sort=Relevance&size=10&page=1#top (Accessed 1 June 2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Mark Yates is funded by the BSR. James Galloway is on the RCOphth hydroxychloroquine guidelines committee. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yates, M., Malaiya, R., Stack, J. et al. Hydroxychloroquine use: the potential impact of new ocular screening guidelines. Eye 32, 161–162 (2018). https://doi.org/10.1038/eye.2017.166
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/eye.2017.166
This article is cited by
-
The incidence, monitoring coverage and clinical characteristics of hydroxychloroquine retinopathy in the United Kingdom
Eye (2024)
-
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom
Eye (2023)
-
Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria
Eye (2021)
-
The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary
Eye (2018)
